Adam Bayes

Dr Bayes MB BS (Hons), BSc (Advanced), MPsychiatry, PhD, FRANZCP, is a psychiatrist and clinician-scientist. Bayes is an early-career researcher focused on mood disorders, working part-time as a senior research fellow at the Black Dog Institute (BDI) and Faculty of Medicine, UNSW. Adam also works part-time as a consultant psychiatrist treating patients with complex mood disorders (unipolar and bipolar conditions) with novel treatments such as ketamine based at the BDI neurostimulation clinic and in private practice.

Bayes has published 42 peer-reviewed publications and one book chapter. His research interest into novel pharmacological treatments for depression began with ketamine. He is currently involved in multiple RCTs comparing differing formulations of ketamine for treatment-resistant depression (TRD) and ketamine for bipolar depression. He co-authored the first published structured instrument to measure ketamine safety, the Ketamine Side Effect Tool; contributed to the national guidelines on ketamine therapy for depression; and co-convenes a biannual ketamine seminar with Prof Colleen Loo, training psychiatrists across Australasia. As a natural extension of his work in ketamine he has expanded into classical psychedelics and is currently involved in a microdose psilocybin RCT for moderate severity depression based at Macquarie University and a dosing study of psilocybin assisted therapy in TRD being led by BDI and St Vincent’s Hospital, Sydney. Bayes provides research supervision to higher degree students, medical students as well as clinical supervision to psychiatry registrars.